Technological Offers

Method to predict cancer response to treatment with anti-PD1 immunotherapy.

Description


Cancer is one of the most studied diseases nowadays because of its mortality and incidence. There are several treatments for this disease, but its effectivity depends on the cancer type and the patient profile.
Cancer treatment with immune checkpoint blockade (ICB) has a long response in responder patients and an acceptable toxicity, so it is a very good treatment for cancer. It is very usual the administration of a ligand of programmed cell death protein 1 inhibitor (anti-PD1) as a treatment for advanced melanoma patient. This treatment has a 20% high response than chemotherapy and patients are usually more tolerable.
Sin embargo, un porcentaje de los pacientes son insensibles o desarrollan resistencia, por lo que es necesario tener un patrón de biomarcadores predictivos que permita decidir el uso o no de anti-PD1.
However, a percentage of the patients are insensible or develop resistance to the treatment. To prevent the use of this treatment with non-response patients, a research group has developed a biomarker profile based on difference in gene expression to classify patients by their response profile.

Advantages


  • This enables doctor to determine if anti-PD1 treatment is suitable in advance
  • It reduces the economic costs and adverse effects associated with the use of unresponsive treatments for certain patients.

Diagnosis


IBIMA Plataforma BIONAND inventors


MARÍA ISABEL BARRAGÁN MALLOFRET
Research group of IBIMA involved: B-05

MARTINA ÁLVAREZ PÉREZ
Research group of IBIMA involved: B-01

MIGUEL ÁNGEL BERCIANO GUERRERO
Research group of IBIMA involved: BE-23

MANUEL COBO DOLS
Research group of IBIMA involved: B-22

ALICIA GARRIDO ARANDA
Research group of IBIMA involved: B-01

ALFONSO SÁNCHEZ MUÑOZ
Research group of IBIMA involved: B-01

FRANCISCO JAVIER OLIVER MARTOS
Research group of IBIMA involved: B-05

EMILIO ALBA CONEJO
Research group of IBIMA involved: B-01

Contact


Innovation and Technology Transfer Office of IBIMA Plataforma BIONAND

transferenacia@ibima.eu